Pharma Integrates 2020 Track 1
Recession, a global pandemic, Brexit – it’s fair to say the events of the past decade have shaped the pharma industry landscape. How has it responded to these challenges and how can it make the most of future opportunities? How will innovation in product quality, manufacturing and working practises drive future productivity?
Welcome and opening remarks
2030 here we come
The pharma and lifesciences ecosystem was already facing significant opportunities and disruption from technology advances, pricing pressure, digital and new entrants. In a Covid-19 world and with Brexit uncertainty the level of disruption has only been amplified. This panel will explore the disruptive themes and key success factors for companies to navigate our changing environment.
JO PISANI | Strategic Advisor, Non Executive Director and Charity Trustee
JOHN DAWSON | Chief Executive Officer | Oxford Biomedica
RICHARD TORBETT | Chief Executive Officer | ABPI
BRIAN HENRY | Vice President, Global Head of Drug Product Design | Pfizer Worldwide Research and Development
GLENN CROCKER | Head of Life Sciences, JLL & Chairman, BioCity Group | JLL & BioCity Group
NICOLE MATHER | Executive Partner, Life Sciences Lead | IBM Services
Brexit – cliff edge or catapult?
With the end of the transition period insight, will Brexit bring a fanfare or a frenzy to Pharma?
CLAIRE THOMPSON | Chief Executive Officer | Agility Life Sciences
SCOTT JOHNSTONE | Chief Executive Officer | Scottish Lifesciences Association
HUGO FRY | Managing Director & Vice President | Sanofi UK & ABPI
TAMSIN BERRY | Director | PHP
JON NEAL | Managing Director | Takeda UK & Ireland
TASMINA GORAYA | Partner, IP and Life Sciences Regulatory | Taylor Wessing
Taking stock: Impact on supply chains in a post-Covid world
The COVID 19 virus pandemic has rocked the world to its core. There are likely to be many and far-reaching consequences of this on the Pharmaceutical industry. One aspect that will come under scrutiny is in the area of risk management and continuity of Pharmaceutical supply chains. What have we learned that will shape supply chains of the future? What innovations have been accelerated to address the challenges? Will we see radical changes in the factors pharma companies consider when making outsourcing decisions? Will they recalculate the balance between working capital and inventory management? Will large companies consider a slowing or even reversal in the trend to outsource API/DP manufacture, with greater investment in internal assets?
ALEX ROBERTSON | Senior Director, Global Clinical Supply Chain | AstraZeneca
JIM FOX | VP & Site Director, PSC Ware Site | GlaxoSmithKline
PETER LYFORD | Business Development Director | Porton Pharma Solutions
MARC CREUS | Head of Business Development | Juvabis Therapeutics
SEAMUS RYAN | Head of Supply Chain and Project Management | SK Biotek Ireland
Innovations in pharma manufacturing have tremendous promise to unlock product quality and manufacturing productivity.
IAN MUIR | Director, Healthcare & Lifesciences | Innovate UK
ALASTAIR FLORENCE | Director, Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub | University of Strathclyde
ALASTAIR COUPE | Senior Director, Drug Product Design, Pharmaceutical Sciences | Pfizer Ltd
DAVE TUDOR | Managing Director, Medicines Manufacturing Innovation Centre | CPI
HASSAN MUMTAZ | Senior Manager (Application) | Applied Materials
MIKE GIBSON | Chief Technical Officer | Sterling Pharma Solutions
Fireside Chat, An interview with Andy Plump
In discussion with Andy Plump President, Research & Development, Takeda Pharmaceutical Company.
Topics will include the international collaborative initiatives on COVID-19 R&D, the status of progress on vaccines and therapeutic agents, data sharing and possible new partnerships for preparedness for the next pandemics.
Conducted by Trevor Jones CBE
Virtual Drinks Reception
Sponsored By: Medicines Manufacturing Innovation Centre, CPI